138 related articles for article (PubMed ID: 37856917)
21. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis.
Sabeena S; Kuriakose S; Damodaran B; Ravishankar N; Arunkumar G
J Gynecol Oncol; 2020 Mar; 31(2):e20. PubMed ID: 31912676
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai, China revealed the limitations of current HPV-based screening and HPV vaccine.
Ruan Y; Li H; Liu M; Cao G; Xu X; Han L; Li F
Cancer Epidemiol; 2023 Jun; 84():102372. PubMed ID: 37119603
[TBL] [Abstract][Full Text] [Related]
24. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
Sivars L; Palsdottir K; Crona Guterstam Y; Falconer H; Hellman K; Tham E
Int J Cancer; 2023 Jun; 152(11):2232-2242. PubMed ID: 36274628
[TBL] [Abstract][Full Text] [Related]
25. Lymph node human papillomavirus DNA positivity in uterine cervical cancers and its relationship with prognostic factors.
Baser E; Can F; Unlukaplan M; Ayhan A
Int J Gynecol Cancer; 2011 Jan; 21(1):117-22. PubMed ID: 21330836
[TBL] [Abstract][Full Text] [Related]
26. Neovaginal Human Papillomavirus Prevalence in Transfeminine Individuals: A Systematic Review.
Nandwana D; Hawes K; Zuend CF; Pope R
Obstet Gynecol; 2023 Aug; 142(2):296-306. PubMed ID: 37411025
[TBL] [Abstract][Full Text] [Related]
27. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
28. Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.
Onuki M; Matsumoto K; Sakurai M; Ochi H; Minaguchi T; Satoh T; Yoshikawa H
J Gynecol Oncol; 2016 Jan; 27(1):e3. PubMed ID: 26463429
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implication of human papillomavirus types and species in cervical cancer patients undergoing primary treatment.
Lau YM; Cheung TH; Yeo W; Mo F; Yu MY; Lee KM; Ho WC; Yeung AC; Law PT; Chan PK
PLoS One; 2015; 10(4):e0122557. PubMed ID: 25855986
[TBL] [Abstract][Full Text] [Related]
30. [Assessment of the diagnostic value and prognosis of different detection markers in endocervical adenocarcinoma].
Zhang CN; Liu XY; Li Q; Song YZ; Liu B; Yin J; Yang JH; Zhong L; Sun L; Zhang X; Chen W
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):402-409. PubMed ID: 37188625
[No Abstract] [Full Text] [Related]
31. A systematic review and meta-analysis of the diagnostic effectiveness of human papillomavirus methylation biomarkers for detection of cervical cancer.
Hillyar CR; Kanabar SS; Pufal KR; Lawson AW; Saw Hee JL; Rallis KS; Nibber A; Sideris M
Epigenomics; 2022 Sep; 14(18):1055-1072. PubMed ID: 36169190
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study.
Schwartz SM; Daling JR; Shera KA; Madeleine MM; McKnight B; Galloway DA; Porter PL; McDougall JK
J Clin Oncol; 2001 Apr; 19(7):1906-15. PubMed ID: 11283122
[TBL] [Abstract][Full Text] [Related]
33. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
34. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery.
Turco LC; Pedone Anchora L; Fedele C; Inzani F; Piermattei A; Martini M; Volpe M; Marchetti S; Santangelo R; Bizzarri N; Cosentino F; Vargiu V; De Ninno M; Macchia G; Valentini V; Zannoni G; Scambia G; Ferrandina G
Int J Gynecol Cancer; 2023 Apr; 33(4):489-497. PubMed ID: 36720505
[TBL] [Abstract][Full Text] [Related]
36. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of human papillomavirus DNA and p16
Li Z; Liu P; Wang Z; Zhang Z; Chen Z; Chu R; Li G; Han Q; Zhao Y; Li L; Miao J; Kong B; Song K
Lancet Oncol; 2023 Apr; 24(4):403-414. PubMed ID: 36933562
[TBL] [Abstract][Full Text] [Related]
38. HPV- and node status in cervical cancer long-term results.
Póka R; Czeglédy J
Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):169-72. PubMed ID: 9138961
[TBL] [Abstract][Full Text] [Related]
39. Effect of Human Papillomavirus Subtype on the Rate of Positive Surgical Margin After Cervical Conization.
Purut YE; Giray B; Akis S; Peker EK; Babayeva G; Kabaca C; Api M
Int J Surg Pathol; 2023 Feb; 31(1):20-25. PubMed ID: 36514291
[No Abstract] [Full Text] [Related]
40. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
